Acute Repetitive Seizures market deals with the medications which prevent seizures in the patients especially suffering from epilepsy. The drugs used in this segment are USL-261, NRL-1, AZ-002, Diastat Rectal Gel. The market is currently led by generic drugs which mainly include oral benzodiazepines (diazepam and lorazepam). Rectal diazepam is the only approved drug for use in U.S. and buccal midazolam in European Union.
Market Overview and Trends
On the basis of product, NRL-1 is expected to be the fastest-growing segment over the forecast period used for children, adolescents, and adultsdesigned for intranasal administration for outpatient use. The USL-261 and VALTOCO have been granted orphan drug designation, and because of their oral route of administration will be have larger market share.
As per geographical breakdown, North America will be the dominant market due toincreasing disease prevalence of epilepsy. Other advanced economies like Germany will see robust growth due to technological advancements in scientific, clinical, and medical fields. Positive government initiatives taken to improve the quality of life of the people will drive the market further.
Asia Pacific will see the maximum growth due to high prevalence of the disease and huge demand for the antiseizure drugs in these developing countries which will encourages a shift in market potential from the already saturated European and North American regions to such economies.
Factors Influencing the Market Growth:
• High unmet clinical needs for patients, as well as caregivers
• Availability of advanced product pipeline
• Healthcare reforms to reduce hospital stays and on-site patient treatment costs through outpatient care models
Factors Restraining the Market Growth:
• Drug induced seizures, adverse reactions
• Lack of antiepileptogenic agents that can prevent development of seizures and its comorbidities
Market Segmentation 2019-2029:
The Acute Repetitive Seizures market is segmented by Product (USL-261, NRL-1, AZ-002, Diastat Rectal Gel), By Region and Segment Forecasts.
Market Segmentation Covered:
• Global Acute Repetitive Seizures Product Market 2019-2029
• Global USL-261 Market 2019-2029
• Global NRL-1 Market 2019-2029
• Global AZ-002 Market 2019-2029
• Global Diastat Rectal Gel Market 2019-2029
• Global Others Market 2019-2029
Geographic Breakdown
Focused regional forecasts and analysis explore the future opportunities:
• North America Market, 2019-2029
• Europe Market, 2019-2029
• Asia-Pacific Market, 2019-2029
• LAMEA Market, 2019-2029
Competitive Analysis:
• Research and development is the primary strategy adopted by the key players in the Acute Repetitive Seizures market.
• These companies have developed various strategies and developments such as product launch, partnerships, mergers & acquisitions, joint venture, and collaborations.
Major Market Players:
UCB S.A. Belgium, Neurelis, Valeant Pharmaceuticals North America LLC., Alexza Pharmaceuticals, VERITON PHARMA and others
Key questions answered by this report:
• What is the current size of the total global Acute Repetitive Seizures market?
• How much will this market be worth from 2018 to 2029?
• How is the Acute Repetitive Seizures market evolving?
• What is driving and restraining the Acute Repetitive Seizures market?
• What are the market shares of each segment of the overall Acute Repetitive Seizures market currently and how will these change to 2029?
• What are the main submarkets and how much revenue will each Acute Repetitive Seizures market submarket account for over the next 10 years to 2029 and why?
• How will the market shares for each Acute Repetitive Seizures market submarket develop from 2018 to 2029?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve to 2029?
• What are the largest national markets for Acute Repetitive Seizures market? What is the current status and how will it develop over the next ten years? What are their forecasts for 2019-2029?
• Who are the most prominent companies, and what are their activities and outlooks?
• What are the main trends that will affect the Acute Repetitive Seizures market between 2018 and 2029?
Visiongain’s study is intended for anyone requiring commercial analyses for the Acute Repetitive Seizures market. You find data, trends and predictions.
Buy our report today Acute Repetitive Seizures Market : By Product (USL-261, NRL-1, AZ-002, Diastat Rectal Gel), By Region and Segment Forecasts.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1 Report Overview
1.1 Global Acute Repetitive Seizures Market
1.2 Global Acute Repetitive Seizures Market Overview
1.3 Global Acute Repetitive Seizures Market Segmentation
1.4 Market Drivers
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report Include:
1.8 Methodology
1.8.1 Secondary Research
1.8.2 Market Evaluation & Forecasting Methodology
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2 Introduction to the Acute Repetitive Seizures Market
2.1 Acute Repetitive Seizures Product
2.1.1 USL-261
2.1.2 NRL-1
2.1.3 AZ-002
2.1.4 Diastat Rectal Gel
2.1.5 Others
3 Global Acute Repetitive Seizures Market Analysis
3.1 PEST Analysis of the Acute Repetitive Seizures Market
3.2 Expert Opinion
3.2.1 Primary Correspondents
3.3 Acute Repetitive Seizures Market Outlook
3.4 Drivers & Restraints
3.5 Dominant Region/Country
3.6 Acute Repetitive Seizures Overall Operating Scenario
3.7 Overall Growth Rate, Globally
3.8 SWOT Analysis of the Acute Repetitive Seizures Market
3.8.1 Strengths
3.8.2 Weaknesses
3.8.3 Opportunities
3.8.4 Threats
4 Acute Repetitive Seizures: Global Market
4.1 Global Acute Repetitive Seizures Product Market 2019-2029
4.1.1 Global USL-261 Market 2019-2029
4.1.2 Global NRL-1 Market 2019-2029
4.1.3 Global AZ-002 Market 2019-2029
4.1.4 Global Diastat Rectal Gel Market 2019-2029
4.1.5 Global Others Market 2019-2029
5 Leading Regions in Acute Repetitive Seizures Market 2019-2029
5.1 Regional Overview
5.1.1 North America
5.1.2 Europe
5.1.3 Asia-Pacific
5.1.4 Middle East & Africa
5.1.5 Rest of the World
5.1.6 Leading Countries/ Regions by Acute Repetitive Seizures Market
5.2 Canada Acute Repetitive Seizures Market 2019-2029
5.2.1 Canada Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
5.2.2 Canada Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
5.2.3 Canada Acute Repetitive Seizures Market Analysis
5.3 U.S. Acute Repetitive Seizures Market 2019-2029
5.3.1 U.S. Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
5.3.2 U.S. Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
5.3.3 U.S. Acute Repetitive Seizures Market Analysis
5.4 Germany Acute Repetitive Seizures Market 2019-2029
5.4.1 Germany Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
5.4.2 Germany Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
5.4.3 Germany Acute Repetitive Seizures Market Analysis
5.5 France Acute Repetitive Seizures Market 2019-2029
5.5.1 France Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
5.5.2 France Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
5.5.3 France Acute Repetitive Seizures Market Analysis
5.6 U.K. Acute Repetitive Seizures Market 2019-2029
5.6.1 U.K. Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
5.6.2 U.K. Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
5.6.3 U.K. Acute Repetitive Seizures Market Analysis
5.7 Italy Acute Repetitive Seizures Market 2019-2029
5.7.1 Italy Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
5.7.2 Italy Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
5.7.3 Italy Acute Repetitive Seizures Market Analysis
5.8 Spain Acute Repetitive Seizures Market 2019-2029
5.8.1 Spain Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
5.8.2 Spain Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
5.8.3 Spain Acute Repetitive Seizures Market Analysis
5.9 China Acute Repetitive Seizures Market 2019-2029
5.9.1 China Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
5.9.2 China Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
5.9.3 China Acute Repetitive Seizures Market Analysis
5.10 Australia Acute Repetitive Seizures Market 2019-2029
5.10.1 Australia Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
5.10.2 Australia Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
5.10.3 Australia Acute Repetitive Seizures Market Analysis
5.11 India Acute Repetitive Seizures Market 2019-2029
5.11.1 India Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
5.11.2 India Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
5.11.3 India Acute Repetitive Seizures Market Analysis
5.12 Indonesia Acute Repetitive Seizures Market 2019-2029
5.12.1 Indonesia Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
5.12.2 Indonesia Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
5.13 India Acute Repetitive Seizures Market 2019-2029
5.13.1 India Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
5.13.2 India Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
5.13.3 India Acute Repetitive Seizures Market Analysis
5.14 South Korea Acute Repetitive Seizures Market 2019-2029
5.14.1 5.13.1 South Korea Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
5.14.2 South Korea Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
5.14.3 South Korea Acute Repetitive Seizures Market Analysis
5.15 Rest of Asia Acute Repetitive Seizures Market 2019-2029
5.15.1 Rest of Asia Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
5.15.2 Rest of Asia Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
5.15.3 Rest of Asia Acute Repetitive Seizures Market Analysis
5.16 Middle East Acute Repetitive Seizures Market 2019-2029
5.16.1 Middle East Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
5.16.2 Middle East Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
5.16.3 Middle East Acute Repetitive Seizures Market Analysis
5.17 Africa Acute Repetitive Seizures Market 2019-2029
5.17.1 Africa Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
5.17.2 Africa Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
5.17.3 Africa Acute Repetitive Seizures Market Analysis
5.18 Rest of the World Acute Repetitive Seizures Market 2019-2029
5.18.1 Rest of the World Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
5.18.2 Rest of the World Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
5.18.3 Rest of the World Acute Repetitive Seizures Market Analysis
6 7. Leading Companies in the Acute Repetitive Seizures Market
6.1 UCB S.A.
6.1.1 Company Overview
6.1.2 Product And Services Overview
6.1.3 Financials Overview
6.1.4 Key Developments
6.1.5 SWOT Analysis
6.2 Neurelis, Inc.
6.2.1 Company Overview
6.2.2 Product And Services Overview
6.2.3 Financial Overview
6.2.4 Key Developments
6.2.5 SWOT Analysis
6.3 Valeant Pharmaceuticals North America LLC.
6.3.1 Company Overview
6.3.2 Product And Services Overview
6.3.3 Financial Overview
6.3.4 Key Development
6.3.5 SWOT Analysis
6.4 Alexza Pharmaceuticals
6.4.1 Company Overview
6.4.2 Product And Services Overview
6.4.3 Financial Overview
6.4.4 Key Development
6.4.5 SWOT Analysis
6.5 Veriton Pharma
6.5.1 Company Overview
6.5.2 Product And Services Overview
6.5.3 Financial Overview
6.5.4 Key Developments
6.5.5 SWOT Analysis
6.6 Sanofi
6.6.1 Company Overview
6.6.2 Product And Services Overview
6.6.3 Financial Overview
6.6.4 Key Developments
6.6.5 SWOT Analysis
6.7 Pfizer Inc.
6.7.1 Overview
6.7.2 Product And Services Overview
6.7.3 Financial Overview
6.7.4 Key Developments
6.7.5 SWOT Analysis
6.8 Acorda Therapeutics, Inc.
6.8.1 Overview
6.8.2 Product And Services Overview
6.8.3 Financials
6.8.4 Key Developments
6.8.5 SWOT Analysis
6.9 Upsher-Smith Laboratories, LLC,
6.9.1 Overview
6.9.2 Product And Services Overview
6.9.3 Financials
6.9.4 Key Developments
6.9.5 SWOT Analysis
6.10 Epalex
6.10.1 Overview
6.10.2 Product And Services Overview
6.10.3 Financials
6.10.4 Key Developments
6.10.5 SWOT Analysis
7 Conclusions and Recommendations
7.1 Global Acute Repetitive Seizures Market Outlook
7.2 Recommendations
8 Glossary
8.1 Associated Visiongain Reports
8.2 Visiongain Report Sales Order Form
8.3 Appendix A
8.4 About Visiongain
8.5 Appendix B
8.6 Visiongain Report Evaluation Form
List of Tables
Table 3.1 PEST Analysis of the Acute Repetitive Seizures Market
Table 3.8 SWOT Analysis of the Acute Repetitive Seizures Market
Table 4.1 Global Acute Repetitive Seizures Product Market 2019-2029
Table 4.1.1 Global USL-261 Market 2019-2029
Table 4.1.2 Global NRL-1 Market 2019-2029
Table 4.1.3 Global AZ-002 Market 2019-2029
Table 4.1.4 Global Diastat Rectal Gel Market 2019-2029
Table 4.1.5 Global Others Market 2019-2029
Table 5.2 Canada Acute Repetitive Seizures Market 2019-2029
Table 5.2.1 Canada Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Table 5.2.2 Canada Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Table 5.2.3 Canada Acute Repetitive Seizures Market Analysis
Table 5.3 U.S. Acute Repetitive Seizures Market 2019-2029
Table 5.3.1 U.S. Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Table 5.3.2 U.S. Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Table 5.3.3 U.S. Acute Repetitive Seizures Market Analysis
Table 5.4 Germany Acute Repetitive Seizures Market 2019-2029
Table 5.4.1 Germany Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Table 5.4.2 Germany Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Table 5.4.3 Germany Acute Repetitive Seizures Market Analysis
Table 5.5 France Acute Repetitive Seizures Market 2019-2029
Table 5.5.1 France Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Table 5.5.2 France Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Table 5.5.3 France Acute Repetitive Seizures Market Analysis
Table 5.6 U.K. Acute Repetitive Seizures Market 2019-2029
Table 5.6.1 U.K. Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Table 5.6.2 U.K. Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Table 5.6.3 U.K. Acute Repetitive Seizures Market Analysis
Table 5.7 Italy Acute Repetitive Seizures Market 2019-2029
Table 5.7.1 Italy Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Table 5.7.2 Italy Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Table 5.7.3 Italy Acute Repetitive Seizures Market Analysis
Table 5.8 Spain Acute Repetitive Seizures Market 2019-2029
Table 5.8.1 Spain Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Table 5.8.2 Spain Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Table 5.8.3 Spain Acute Repetitive Seizures Market Analysis
Table 5.9 China Acute Repetitive Seizures Market 2019-2029
Table 5.9.1 China Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Table 5.9.2 China Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Table 5.9.3 China Acute Repetitive Seizures Market Analysis
Table 5.10 Australia Acute Repetitive Seizures Market 2019-2029
Table 5.10.1 Australia Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Table 5.10.2 Australia Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Table 5.10.3 Australia Acute Repetitive Seizures Market Analysis
Table 5.11 India Acute Repetitive Seizures Market 2019-2029
Table 5.11.1 India Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Table 5.11.2 India Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Table 5.11.3 India Acute Repetitive Seizures Market Analysis
Table 5.12 Indonesia Acute Repetitive Seizures Market 2019-2029
Table 5.12.1 Indonesia Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Table 5.12.2 Indonesia Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Table 5.13 India Acute Repetitive Seizures Market 2019-2029
Table 5.13.1 India Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Table 5.13.2 India Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Table 5.13.3 India Acute Repetitive Seizures Market Analysis
Table 5.14 South Korea Acute Repetitive Seizures Market 2019-2029
Table 5.14.1 5.13.1 South Korea Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Table 5.14.2 South Korea Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Table 5.14.3 South Korea Acute Repetitive Seizures Market Analysis
Table 5.15 Rest of Asia Acute Repetitive Seizures Market 2019-2029
Table 5.15.1 Rest of Asia Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Table 5.15.2 Rest of Asia Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Table 5.15.3 Rest of Asia Acute Repetitive Seizures Market Analysis
Table 5.16 Middle East Acute Repetitive Seizures Market 2019-2029
Table 5.16.1 Middle East Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Table 5.16.2 Middle East Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Table 5.16.3 Middle East Acute Repetitive Seizures Market Analysis
Table 5.17 Africa Acute Repetitive Seizures Market 2019-2029
Table 5.17.1 Africa Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Table 5.17.2 Africa Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Table 5.17.3 Africa Acute Repetitive Seizures Market Analysis
Table 5.18 Rest of the World Acute Repetitive Seizures Market 2019-2029
Table 5.18.1 Rest of the World Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Table 5.18.2 Rest of the World Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Table 5.18.3 Rest of the World Acute Repetitive Seizures Market Analysis
Table 6.1.3 UCB S.A. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.1.5 UCB S.A. Total Company Sales 2014-2019 (US$ bn, AGR %)
Table 6.2.3 Neurelis, Inc. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.2.5 Neurelis, Inc. Total Company Sales 2014-2019 (US$ bn, AGR %)
Table 6.3.3 Valeant Pharmaceuticals North America LLC. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.3.5 Valeant Pharmaceuticals North America LLC. Total Company Sales 2014-2019 (US$ bn, AGR %)
Table 6.4.3 Alexza Pharmaceuticals Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.4.5 Alexza Pharmaceuticals Total Company Sales 2014-2019 (US$ bn, AGR %)
Table 6.5.3 Veriton Pharma Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.5.5 Veriton Pharma Total Company Sales 2014-2019 (US$ bn, AGR %)
Table 6.6.3 Sanofi Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.6.5 Sanofi Total Company Sales 2014-2019 (US$ bn, AGR %)
Table 6.7.3 Pfizer Inc. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.7.5 Pfizer Inc. Total Company Sales 2014-2019 (US$ bn, AGR %)
Table 6.8.3 Acorda Therapeutics, Inc. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.8.5 Acorda Therapeutics, Inc. Total Company Sales 2014-2019 (US$ bn, AGR %)
Table 6.9.3 Upsher-Smith Laboratories, LLC, Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.9.5 Upsher-Smith Laboratories, LLC, Total Company Sales 2014-2019 (US$ bn, AGR %)
Table 6.10.3 Epalex Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Table 6.10.5 Epalex Total Company Sales 2014-2019 (US$ bn, AGR %)
List of Figures
Figure 1.1 Global Acute Repetitive Seizures Market Segmentation
Figure 4.1 Global Acute Repetitive Seizures Product Market 2019-2029
Figure 4.1.1 Global USL-261 Market 2019-2029
Figure 4.1.2 Global NRL-1 Market 2019-2029
Figure 4.1.3 Global AZ-002 Market 2019-2029
Figure 4.1.4 Global Diastat Rectal Gel Market 2019-2029
Figure 4.1.5 Global Others Market 2019-2029
Figure 5.2 Canada Acute Repetitive Seizures Market 2019-2029
Figure 5.2.1 Canada Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Figure 5.2.2 Canada Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Figure 5.2.3 Canada Acute Repetitive Seizures Market Analysis
Figure 5.3 U.S. Acute Repetitive Seizures Market 2019-2029
Figure 5.3.1 U.S. Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Figure 5.3.2 U.S. Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Figure 5.3.3 U.S. Acute Repetitive Seizures Market Analysis
Figure 5.4 Germany Acute Repetitive Seizures Market 2019-2029
Figure 5.4.1 Germany Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Figure 5.4.2 Germany Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Figure 5.4.3 Germany Acute Repetitive Seizures Market Analysis
Figure 5.5 France Acute Repetitive Seizures Market 2019-2029
Figure 5.5.1 France Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Figure 5.5.2 France Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Figure 5.5.3 France Acute Repetitive Seizures Market Analysis
Figure 5.6 U.K. Acute Repetitive Seizures Market 2019-2029
Figure 5.6.1 U.K. Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Figure 5.6.2 U.K. Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Figure 5.6.3 U.K. Acute Repetitive Seizures Market Analysis
Figure 5.7 Italy Acute Repetitive Seizures Market 2019-2029
Figure 5.7.1 Italy Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Figure 5.7.2 Italy Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Figure 5.7.3 Italy Acute Repetitive Seizures Market Analysis
Figure 5.8 Spain Acute Repetitive Seizures Market 2019-2029
Figure 5.8.1 Spain Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Figure 5.8.2 Spain Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Figure 5.8.3 Spain Acute Repetitive Seizures Market Analysis
Figure 5.9 China Acute Repetitive Seizures Market 2019-2029
Figure 5.9.1 China Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Figure 5.9.2 China Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Figure 5.9.3 China Acute Repetitive Seizures Market Analysis
Figure 5.10 Australia Acute Repetitive Seizures Market 2019-2029
Figure 5.10.1 Australia Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Figure 5.10.2 Australia Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Figure 5.10.3 Australia Acute Repetitive Seizures Market Analysis
Figure 5.11 India Acute Repetitive Seizures Market 2019-2029
Figure 5.11.1 India Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Figure 5.11.2 India Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Figure 5.11.3 India Acute Repetitive Seizures Market Analysis
Figure 5.12 Indonesia Acute Repetitive Seizures Market 2019-2029
Figure 5.12.1 Indonesia Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Figure 5.12.2 Indonesia Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Figure 5.13 India Acute Repetitive Seizures Market 2019-2029
Figure 5.13.1 India Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Figure 5.13.2 India Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Figure 5.13.3 India Acute Repetitive Seizures Market Analysis
Figure 5.14 South Korea Acute Repetitive Seizures Market 2019-2029
Figure 5.14.1 5.13.1 South Korea Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Figure 5.14.2 South Korea Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Figure 5.14.3 South Korea Acute Repetitive Seizures Market Analysis
Figure 5.15 Rest of Asia Acute Repetitive Seizures Market 2019-2029
Figure 5.15.1 Rest of Asia Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Figure 5.15.2 Rest of Asia Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Figure 5.15.3 Rest of Asia Acute Repetitive Seizures Market Analysis
Figure 5.16 Middle East Acute Repetitive Seizures Market 2019-2029
Figure 5.16.1 Middle East Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Figure 5.16.2 Middle East Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Figure 5.16.3 Middle East Acute Repetitive Seizures Market Analysis
Figure 5.17 Africa Acute Repetitive Seizures Market 2019-2029
Figure 5.17.1 Africa Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Figure 5.17.2 Africa Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Figure 5.17.3 Africa Acute Repetitive Seizures Market Analysis
Figure 5.18 Rest of the World Acute Repetitive Seizures Market 2019-2029
Figure 5.18.1 Rest of the World Acute Repetitive Seizures Submarket, By Products Type (USL-261, NRL-1, AZ-002 & Diastat Rectal Gel) Forecast 2019-2029
Figure 5.18.2 Rest of the World Acute Repetitive Seizures Submarket, By Others Products Type Forecast 2019-2029
Figure 5.18.3 Rest of the World Acute Repetitive Seizures Market Analysis
Figure 6.1.3 UCB S.A. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.1.5 UCB S.A. Total Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.2.3 Neurelis, Inc. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.2.5 Neurelis, Inc. Total Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.3.3 Valeant Pharmaceuticals North America LLC. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.3.5 Valeant Pharmaceuticals North America LLC. Total Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.4.3 Alexza Pharmaceuticals Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.4.5 Alexza Pharmaceuticals Total Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.5.3 Veriton Pharma Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.5.5 Veriton Pharma Total Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.6.3 Sanofi Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.6.5 Sanofi Total Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.7.3 Pfizer Inc. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.7.5 Pfizer Inc. Total Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.8.3 Acorda Therapeutics, Inc. Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.8.5 Acorda Therapeutics, Inc. Total Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.9.3 Upsher-Smith Laboratories, LLC, Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.9.5 Upsher-Smith Laboratories, LLC, Total Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.10.3 Epalex Profile 2019 (Market Entry, Public/Private, Headquarter, Total Company Revenue $bn, Change in Revenue, Geography, Key Market, Listed on, Products/Services, No. of Employees)
Figure 6.10.5 Epalex Total Company Sales 2014-2019 (US$ bn, AGR %)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
